Management of chronic HBV-HDV patients chronic HBV-HDV infection: A review on new management options

Hepatitis D virus was first described by Mario Rizzeto in 1977, and it is considered chronic viral hepatitis with the poorest prognosis. Despite its discovery almost 50 years ago, progress in its diagnosis and treatment has been scarce until recent years. The approval of bulevirtide has shed some light for patients with Chronic Hepatitis D, although important gaps regarding its use in therapy as well as about the epidemiology and diagnosis of the disease need to be addressed.

 

Comments:

Absolutely, Hepatitis D, caused by the Hepatitis D virus (HDV), indeed presents significant challenges in both diagnosis and treatment. Mario Rizzetto's discovery was a critical step in understanding this virus, but progress in managing the disease has been slow.

Bulevirtide's approval marks a significant milestone in the treatment landscape for Chronic Hepatitis D. Its introduction has provided hope for patients, especially considering the historically limited options available. However, you're right; there are still gaps in our understanding and management of the disease.

Improving therapy through a deeper comprehension of the virus, refining diagnostic methods, and expanding epidemiological knowledge are crucial steps toward addressing these gaps. Further research and development efforts are necessary to enhance treatment efficacy, broaden therapeutic options, and advance diagnostic accuracy.

Continued efforts in research, clinical trials, and medical advancements will be vital in filling these gaps and improving outcomes for individuals affected by Chronic Hepatitis D.

Related Products

Cat.No.	Product Name	Information
P1105	Bulevirtide (Myrcludex B)	Bulevirtide (Myrcludex B) is a sodium-taurocholate co-transporting polypeptide (NTCP) receptor inhibitor with IC50 of ∼80 pM and inactivates NTCP function at concentrations far below those required to block bile salt transport.

Related Targets

Others